Alemtuzumab

国际站：Alemtuzumab

中文名：阿伦单抗

CAS：216503-57-0

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Alemtuzumab (Campath-IH) 是一种针对 CD52 的人源化单克隆抗体，CD52 是一种在大多数淋巴细胞表面表达的糖蛋白，在较小程度上表达于骨髓细胞类型。 Alemtuzumab 选择性靶向 CD52 抗原以诱导淋巴细胞深度耗竭，随后恢复具有调节表型的 T 和 B 细胞^[1][2]。

体内：Alemtuzumab (Campath-IH；0.5-5 mg/kg；腹腔注射；单剂量) 会导致外周血和淋巴器官中 B 和 T 淋巴细胞的剂量依赖性消耗[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: hCD52 transgenic mice[2] Dosage: 0.5-5 mg/kg Administration: IP; a single dose Result: Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs. Clinical Trial

参考文献：[1]. Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12:706278. Published 2021 Oct 28.[2]. Yanping Hu, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128(2):260-70.